{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:43:22Z","timestamp":1781066602269,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C15966\/A24375"],"award-info":[{"award-number":["C15966\/A24375"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C26822, A16484"],"award-info":[{"award-number":["C26822, A16484"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CRUK\/08\/025, A29806"],"award-info":[{"award-number":["CRUK\/08\/025, A29806"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bayer PLC NIHR BRC Grant code A153"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Male sex is associated with worse outcome in acute myeloid leukemia (AML) in many studies. We analyzed the survival of 4281 patients treated with intensive chemotherapy in the AML17 and AML19 trials based on sex. Men had a significantly lower remission rate than women. Men had a higher incidence of adverse cytogenetic features and a lower incidence of the relatively favorable\n                    <jats:italic>NPM1<\/jats:italic>\n                    mutation. However, male sex was an independent risk factor for survival in multi-variate analysis. We hypothesized that androgen signaling in men could worsen outcomes by protecting AML cells from chemotherapy. We demonstrated high levels of androgen receptor (AR) expression in AML across cytogenetic risk groups. We showed the AR expression was induced by IL-6 signaling in vitro and correlates with poor overall survival. Androgens had no effect on survival of primary AML cells in vitro, nor did they impact gene expression. Androgens did not protect AML cells against chemotherapy either in vitro or in vivo. Similar results were observed with estrogen signaling through estrogen receptor in vitro in AML cells. In conclusion, targeting the androgen pathway may not be a promising clinical strategy and sex hormone signaling in AML cells does not explain the poorer outcomes of men.\n                  <\/jats:p>","DOI":"10.1038\/s41375-025-02752-x","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:35:43Z","timestamp":1757597743000},"page":"2895-2906","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Acute myeloid leukaemia cells express high levels of androgen receptor but do not depend on androgen signaling for survival"],"prefix":"10.1038","volume":"39","author":[{"given":"Farideh","family":"Miraki-Moud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Ariza-McNaughton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thinzar","family":"KoKo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jad","family":"Othman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randal","family":"Stronge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8395-8075","authenticated-orcid":false,"given":"Ian","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2236-8852","authenticated-orcid":false,"given":"Amanda","family":"Gilkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1734-5817","authenticated-orcid":false,"given":"Alan","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro Rodrigues","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0973-660X","authenticated-orcid":false,"given":"Fay","family":"Cafferty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Taussig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Thornhill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4735-5226","authenticated-orcid":false,"given":"Dominique","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9621-0146","authenticated-orcid":false,"given":"David C.","family":"Taussig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"key":"2752_CR1","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1182\/bloodadvances.2021005585","volume":"6","author":"A Bataller","year":"2022","unstructured":"Bataller A, Garrido A, Guijarro F, O\u00f1ate G, Diaz-Bey\u00e1 M, Arnan M, et al. European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. Blood Adv. 2022;6:1193\u2013206.","journal-title":"Blood Adv"},{"key":"2752_CR2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1182\/blood.V108.11.18.18","volume":"108","author":"AK Burnett","year":"2006","unstructured":"Burnett AK, Hills RK, Wheatley K, Goldstone AH, Prentice AG, Milligan D. A sensitive risk score for directing treatment in younger patients with AML. Blood. 2006;108:18.","journal-title":"Blood"},{"key":"2752_CR3","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1182\/blood.2019002697","volume":"135","author":"K D\u00f6hner","year":"2020","unstructured":"D\u00f6hner K, Thiede C, Jahn N, Panina E, Gambietz A, Larson RA, et al. Impact of NPM1\/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood. 2020;135:371\u201380.","journal-title":"Blood"},{"key":"2752_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/bjh.17523","volume":"194","author":"PH Wiernik","year":"2021","unstructured":"Wiernik PH, Sun Z, Cripe LD, Rowe JM, Fernandez HF, Luger SM, et al. Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemia. British J Haematol. 2021;194:309\u201318.","journal-title":"British J Haematol"},{"key":"2752_CR5","doi-asserted-by":"publisher","first-page":"4084","DOI":"10.1200\/JCO.23.02631","volume":"42","author":"J Versluis","year":"2024","unstructured":"Versluis J, Metzner M, Wang A, Gradowska P, Thomas A, Jakobsen NA, et al. Risk stratification in older intensively treated patients with AML. J Clin Oncol. 2024;42:4084\u201394.","journal-title":"J Clin Oncol"},{"key":"2752_CR6","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1038\/s41375-024-02435-z","volume":"38","author":"JM Tettero","year":"2024","unstructured":"Tettero JM, Cloos J, Bullinger L. Acute myeloid leukemia: does sex matter?. Leukemia. 2024;38:2329\u201331.","journal-title":"Leukemia"},{"key":"2752_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41375-023-02068-8","volume":"38","author":"M Ozga","year":"2024","unstructured":"Ozga M, Nicolet D, Mr\u00f3zek K, Yilmaz AS, Kohlschmidt J, Larkin KT, et al. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG). Leukemia. 2024;38:45\u201357.","journal-title":"Leukemia"},{"key":"2752_CR8","doi-asserted-by":"crossref","unstructured":"Tettero J, Dall'Olio D,\u00a0Carota L, Turki A,\u00a0Str\u00e4ng E, Alvarado MA, et al. Sex disparities in genetic landscape of acute myeloid leukemia: a comprehensive analysis using the harmony consortium dataset. In: EHA conference. EHA; 2024.","DOI":"10.1038\/s41375-024-02435-z"},{"key":"2752_CR9","doi-asserted-by":"publisher","first-page":"e2340030","DOI":"10.1001\/jamanetworkopen.2023.40030","volume":"6","author":"KM Pencina","year":"2023","unstructured":"Pencina KM, Travison TG, Artz AS, Lincoff AM, Nissen SE, Flevaris P, et al. Efficacy of testosterone replacement therapy in correcting anemia in men with hypogonadism: a randomized clinical trial. JAMA Netw Open. 2023;6:e2340030\u2013e.","journal-title":"JAMA Netw Open"},{"key":"2752_CR10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1182\/blood.V34.3.283.283","volume":"34","author":"L Sanchez-Medal","year":"1969","unstructured":"Sanchez-Medal L, Gomez-Leal A, Duarte L, Rico MG. Anabolic androgenic steroids in the treatment of acquired aplastic anemia. Blood. 1969;34:283\u2013300.","journal-title":"Blood"},{"key":"2752_CR11","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/1096-9896(0000)9999:9999<::AID-PATH803>3.0.CO;2-W","volume":"193","author":"A Mantalaris","year":"2001","unstructured":"Mantalaris A, Panoskaltsis N, Sakai Y, Bourne P, Chang C, Messing EM, et al. Localization of androgen receptor expression in human bone marrow. J Pathol. 2001;193:361\u20136.","journal-title":"J Pathol"},{"key":"2752_CR12","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1084\/jem.20082521","volume":"206","author":"KH Chuang","year":"2009","unstructured":"Chuang KH, Altuwaijri S, Li G, Lai JJ, Chu CY, Lai KP, et al. Neutropenia with impaired host defense against microbial infection in mice lacking androgen receptor. J Exp Med. 2009;206:1181\u201399.","journal-title":"J Exp Med"},{"key":"2752_CR13","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jsbmb.2011.11.008","volume":"129","author":"LS Inamdar Doddamani","year":"2012","unstructured":"Inamdar Doddamani LS, Jayamma Y. Acceleration of neutrophil precursors\u2019 maturation and immunostimulation of CD3+, CD4+ lymphocytes by stanozolol in mice. J Steroid Biochem Mol Biol. 2012;129:172\u20138.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2752_CR14","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995\u20132005.","journal-title":"N Engl J Med"},{"key":"2752_CR15","doi-asserted-by":"publisher","first-page":"4069","DOI":"10.1200\/JCO.21.01983","volume":"39","author":"AL Ho","year":"2021","unstructured":"Ho AL. Androgen receptor pathway in salivary gland cancer. J Clin Oncol. 2021;39:4069\u201372.","journal-title":"J Clin Oncol"},{"key":"2752_CR16","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1182\/blood-2015-01-623447","volume":"125","author":"AK Burnett","year":"2015","unstructured":"Burnett AK, Russell NH, Hills RK, Kell J, Cavenagh J, Kjeldsen L, et al. A randomized comparison of daunorubicin 90 mg\/m2 vs 60 mg\/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2015;125:3878\u201385.","journal-title":"Blood"},{"key":"2752_CR17","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1200\/JCO.23.00943","volume":"42","author":"NH Russell","year":"2024","unstructured":"Russell NH, Wilhelm-Benartzi C, Othman J, Dillon R, Knapper S, Batten LM, et al. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin with gemtuzumab ozogamicin improves event-free survival in younger patients with newly diagnosed AML and overall survival in patients with NPM1 and FLT3 mutations. J Clin Oncol. 2024;42:1158\u201368.","journal-title":"J Clin Oncol"},{"key":"2752_CR18","first-page":"1773","volume":"7","author":"DL Lin","year":"2001","unstructured":"Lin DL, Whitney MC, Yao Z, Keller ET. Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. Clin Cancer Res. 2001;7:1773\u201381.","journal-title":"Clin Cancer Res"},{"key":"2752_CR19","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41586-018-0266-0","volume":"559","author":"A Calcinotto","year":"2018","unstructured":"Calcinotto A, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M, et al. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature. 2018;559:363\u20139.","journal-title":"Nature"},{"key":"2752_CR20","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1177\/1947601910383417","volume":"1","author":"K Okitsu","year":"2010","unstructured":"Okitsu K, Kanda T, Imazeki F, Yonemitsu Y, Ray RB, Chang C, et al. Involvement of interleukin-6 and androgen receptor signaling in pancreatic cancer. Genes Cancer. 2010;1:859\u201367.","journal-title":"Genes Cancer"},{"key":"2752_CR21","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.molcel.2005.07.018","volume":"19","author":"Q Wang","year":"2005","unstructured":"Wang Q, Carroll JS, Brown M. Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol Cell. 2005;19:631\u201342.","journal-title":"Mol Cell"},{"key":"2752_CR22","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1210\/en.2004-0311","volume":"145","author":"AM Velasco","year":"2004","unstructured":"Velasco AM, Gillis KA, Li Y, Brown EL, Sadler TM, Achilleos M, et al. Identification and validation of novel androgen-regulated genes in prostate cancer. Endocrinology. 2004;145:3913\u201324.","journal-title":"Endocrinology"},{"key":"2752_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul. 1984;22:27\u201355.","journal-title":"Adv Enzym Regul"},{"key":"2752_CR24","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1200\/JCO.2016.67.6213","volume":"35","author":"A Pigneux","year":"2016","unstructured":"Pigneux A, B\u00e9n\u00e9 MC, Guardiola P, Recher C, Hamel J-F, Sauvezie M, et al. Addition of androgens improves survival in elderly patients with acute myeloid leukemia: a GOELAMS study. J Clin Oncol. 2016;35:387\u201393.","journal-title":"J Clin Oncol"},{"key":"2752_CR25","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1182\/bloodadvances.2017007856","volume":"1","author":"AM Stevens","year":"2017","unstructured":"Stevens AM, Miller JM, Munoz JO, Gaikwad AS, Redell MS. Interleukin-6 levels predict event-free survival in pediatric AML and suggest a mechanism of chemotherapy resistance. Blood Adv. 2017;1:1387\u201397.","journal-title":"Blood Adv"},{"key":"2752_CR26","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1002\/1878-0261.13035","volume":"15","author":"M Helles\u00f8y","year":"2021","unstructured":"Helles\u00f8y M, Engen C, Grob T, L\u00f6wenberg B, Valk PJM, Gjertsen BT. Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis. Mol Oncol. 2021;15:2285\u201399.","journal-title":"Mol Oncol"},{"key":"2752_CR27","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1182\/blood.2024024310","volume":"144","author":"J Othman","year":"2024","unstructured":"Othman J, Potter N, Ivey A, Tazi Y, Papaemmanuil E, Jovanovic J, et al. Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML. Blood. 2024;144:714\u201328.","journal-title":"Blood"},{"key":"2752_CR28","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/nature12932","volume":"505","author":"D Nakada","year":"2014","unstructured":"Nakada D, Oguro H, Levi BP, Ryan N, Kitano A, Saitoh Y, et al. Oestrogen increases haematopoietic stem-cell self-renewal in females and during pregnancy. Nature. 2014;505:555\u20138.","journal-title":"Nature"},{"key":"2752_CR29","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454\u201364.","journal-title":"N Engl J Med"},{"key":"2752_CR30","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/jhg.2015.105","volume":"60","author":"L Hyo Kim","year":"2015","unstructured":"Hyo Kim L, Sub Cheong H, Koh Y, Ahn K-S, Lee C, Kim H-L, et al. Cytidine deaminase polymorphisms and worse treatment response in normal karyotype AML. J Hum Genet. 2015;60:749\u201354.","journal-title":"J Hum Genet"},{"key":"2752_CR31","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1158\/1078-0432.CCR-13-0872","volume":"19","author":"RZ Mahfouz","year":"2013","unstructured":"Mahfouz RZ, Koh LS, Teo M, Chee CL, Toh HC, Saunthararajah Y. Gender, cytidine deaminase, and 5-aza\/decitabine-response. Clin Cancer Res. 2013;19:3106\u20137.","journal-title":"Clin Cancer Res"},{"key":"2752_CR32","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/BF00686192","volume":"36","author":"RA Fleming","year":"1995","unstructured":"Fleming RA, Capizzi RL, Rosner GL, Oliver LK, Smith SJ, Schiffer CA, et al. Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B study. Cancer Chemother Pharmacol. 1995;36:425\u201330.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2752_CR33","doi-asserted-by":"publisher","first-page":"e2411726","DOI":"10.1001\/jamanetworkopen.2024.11726","volume":"7","author":"JK Lamba","year":"2024","unstructured":"Lamba JK, Marrero R, Wu H, Cao X, Parcha PK, Karol SE, et al. Pharmacogenomics, race, and treatment outcome in pediatric acute myeloid leukemia. JAMA Netw Open. 2024;7:e2411726\u2013e.","journal-title":"JAMA Netw Open"},{"key":"2752_CR34","doi-asserted-by":"crossref","unstructured":"Rutella S, Vadakekolathu J, Mazziotta F, Reeder S, Yau T-O, Mukhopadhyay R, et al. Immune dysfunction signatures predict outcomes and define checkpoint blockade\u2013unresponsive microenvironments in acute myeloid leukemia. J Clin Invest. 2022;132:e159579.","DOI":"10.1172\/JCI159579"},{"key":"2752_CR35","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nri.2016.90","volume":"16","author":"SL Klein","year":"2016","unstructured":"Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16:626\u201338.","journal-title":"Nat Rev Immunol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02752-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02752-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02752-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T09:10:38Z","timestamp":1763629838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02752-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2752"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02752-x","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,11]]},"assertion":[{"value":"7 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Investigator initiated grant funding from Bayer to DCT.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}